Article
Dermatology
C-B Chen, Y-E Chen, M-T Chu, C-W Wang, R. C-Y Hui, C-W Lu, Y-P Hsiao, C-Y Chu, M. M. Chang, C. M-T Cheung, C-Y Cheng, Y-W Wang, Y-J Lin, C-J Chang, S- Hung, W-H Chung
Summary: Research in Taiwan and Hong Kong focused on characterizing patients with AOA-SCAR, investigating the HLA association, and examining the utility of in vitro diagnostic methods. The study identified strontium ranelate as the most common causality of AOA-SCAR in Asian populations, with HLA-A*33:03 genetic allele being significantly associated with SR-SJS. The sensitivity of lymphocyte activation test (LAT) for identifying the culprit drug of SR-SJS was 83.3%.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2021)
Review
Immunology
Dennis Niebel, Natalija Novak, Jasmin Wilhelmi, Jana Ziob, Dagmar Wilsmann-Theis, Thomas Bieber, Joerg Wenzel, Christine Braegelmann
Summary: Various COVID-19 vaccines can cause injection site reactions, while delayed cutaneous adverse drug reactions may occur days later, necessitating further research. Cutaneous ADRs can be classified based on cytokine expression patterns, with some reactions mimicking immune responses to natural infection with SARS-CoV-2.
Article
Multidisciplinary Sciences
Menglin Jiang, Jin Yang, Linlin Yang, Lina Wang, Ting Wang, Shengna Han, Ye Cheng, Zihua Chen, Yu Su, Lirong Zhang, Fanping Yang, Sheng-an Chen, Jin Zhang, Hao Xiong, Lanting Wang, Zhen Zhang, Li Ma, Xiaoqun Luo, Qinghe Xing
Summary: An association study was conducted to investigate the relationship between human leukocyte antigen (HLA) alleles and levofloxacin-induced severe cutaneous adverse drug reactions (LEV-SCARs). The study found that the carrier frequencies of HLA-B*13:01, HLA-B*13:02, and serotype B13 were significantly higher in patients with LEV-SCARs compared to levofloxacin-tolerant individuals. Molecular docking analysis and mass spectrometry provided insights into the binding and structural changes between levofloxacin and HLA-B*13:01/HLA-B*13:02. Prospective screening for serotype B13 and alternative drug treatment for carriers may reduce the incidence of LEV-SCARs.
Review
Biochemistry & Molecular Biology
Fumi Miyagawa, Hideo Asada
Summary: For severe cutaneous adverse reactions (SCARs) like Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) and drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS), analyzing distinct chemokine profiles can aid in their diagnosis and treatment. It is crucial to identify new therapeutic targets for SCARs, with chemokines playing a key role in the pathogenesis and adjuvant diagnosis of these conditions. Additionally, the association between human herpesvirus 6 (HHV-6) and DIHS/DRESS, as well as the possible roles of chemokine/chemokine receptor homologs encoded by HHV-6 in the pathogenesis, are areas of increasing interest.
Review
Medicine, General & Internal
Shang-Chen Yang, Chun-Bing Chen, Mao-Ying Lin, Zhi-Yang Zhang, Xiao-Yan Jia, Ming Huang, Ya-Fen Zou, Wen-Hung Chung
Summary: In recent years, significant progress has been made in the research of SCARs, including SJS/TEN, particularly in the genetic factors. The identification of genetic alleles associated with drugs related SCARs has been an important breakthrough for the prevention of these severe skin reactions.
FRONTIERS IN MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Therdpong Tempark, Shobana John, Pawinee Rerknimitr, Patompong Satapornpong, Chonlaphat Sukasem
Summary: SCARs are rare and life-threatening hypersensitivity reactions with different clinical and morphological features. Genetic polymorphism of the HLA genes may be associated with drug-induced severe cutaneous reactions, but there may also be other immune pathogenesis involved. This review discusses various aspects of SCARs, including clinical morphology, immune pathogenesis models, diagnostic criteria, treatments, and the application of pharmacogenomics in the prevention of SCARs.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Pharmacology & Pharmacy
Wei Leik Ng, Kheng Seang Lim, Vidhya Hariraj, Sing Chet Lee, Wee Kee Wo, Azuana Ramli, Pauline Siew Mei Lai, Si Lei Fong, Jing Ran Lim
Summary: This study aimed to determine the incidence of allopurinol-induced severe cutaneous adverse drug reactions (SCAR) in Malaysia. The retrospective analysis revealed an average incidence of 2.5 cases per 1000 new users over the 5-year period, with a decreasing trend. Stevens-Johnson syndrome was the most common type of allopurinol-induced SCAR reported. Among the three main ethnicities in Malaysia, the Chinese had the highest percentage of allopurinol-induced SCAR.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2022)
Review
Medicine, General & Internal
Francesco Bellinato, Martina Maurelli, Paolo Gisondi, Giampiero Girolomoni
Summary: This review summarizes the cutaneous adverse reactions associated with SARS-CoV-2 vaccines, categorizing them into new onset reactions and flares of preexisting dermatoses. Injection site reactions are the most common, affecting 30-70% of cases and generally mild or moderate.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Health Care Sciences & Services
Lin Cheng, Bao Sun, Yan Xiong, Lei Hu, Lichen Gao, Ji Li, Hongfu Xie, Xiaoping Chen, Wei Zhang, Hong-Hao Zhou
Summary: This study analyzed the DNA methylation profiling in severe cutaneous adverse reactions (SCARs) induced by allopurinol, and found that this methylation profile is associated with autophagy and microRNAs (miRNAs). The turquoise and yellow modules on the chromosomes were found to be correlated with allopurinol hypersensitivity.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Article
Dermatology
Christina Sze-Man Wong, Chi-Keung Yeung, Chun-Yin Chan, Desmond Yat-Hin Yap, Sydney Chi-Wai Tang, Bernard Man-Yung Cheung, Janette Siu-Yin Kwok, Henry Hin-Lee Chan
Summary: Pre-treatment HLA-B*58:01 screening in Chinese CKD patients can effectively prevent allopurinol-induced severe cutaneous adverse reactions, with cost-effectiveness.
ARCHIVES OF DERMATOLOGICAL RESEARCH
(2022)
Review
Oncology
Vasiliki Nikolaou, Antonis Tsimpidakis, Alexander Stratigos
Summary: Immune checkpoint blockers (ICBs) have been widely used for the treatment of melanoma, but they can also cause autoimmune toxicities, especially in the skin. The role of dermatologists is important in detecting and treating these adverse events. Common cutaneous toxicities include rash, psoriasis-like and lichenoid dermatoses, and bullous pemphigoid. Rare toxicities such as sarcoidosis, dermatomyositis, and subacute lupus have also been reported. This review provides a summary of ICB-induced cutaneous toxicities in melanoma patients and discusses management and treatment options.
Article
Medicine, Research & Experimental
Tsugumichi Sato, Ching-Lan Cheng, Heung-Woo Park, Yea-Huei Kao Yang, Min-Suk Yang, Mizuki Fujita, Yuji Kumagai, Masahiro Tohkin, Yoshiro Saito, Kimie Sai
Summary: This study revealed population differences in the incidence of allopurinol-related severe cutaneous adverse reactions among East Asians, with Taiwan having the highest incidence and Japan the lowest. The differences were influenced by genetic and other common risk factors, indicating the importance of appropriate risk management based on ethnic origins.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2021)
Review
Allergy
Andrew Gibson, Pooja Deshpande, Chelsea N. Campbell, Matthew S. Krantz, Eric Mukherjee, Maja Mockenhaupt, Munir Pirmohamed, Amy M. Palubinsky, Elizabeth J. Phillips
Summary: Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS)/drug-induced hypersensitivity syndrome (DIHS), have significant impact on health and hinder drug development. Understanding the association between HLA class I alleles and SCARs has helped with prevention efforts and shed light on the immunopathogenesis. However, there is still much unknown about the specific risk alleles and antigens involved. Identifying the MHC-restricted drug-reactive peptides and genetic/environmental risk factors will be crucial for predicting individual and drug-level risks and developing targeted therapeutics.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Article
Pharmacology & Pharmacy
Pansakon Wattanachai, Warayuwadee Amornpinyo, Parinya Konyoung, Danklai Purimart, Usanee Khunarkornsiri, Oranuch Pattanacheewapull, Wichittra Tassaneeyakul, Nontaya Nakkam
Summary: This study extensively characterizes the associations between HLA genetic polymorphisms and several phenotypes of beta-lactam antibiotics-related severe cutaneous adverse reactions (SCARs).
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Fiona James, Michelle S. Y. Goh, Effie Mouhtouris, Sara Vogrin, Kyra Y. L. Chua, Natasha E. Holmes, Andrew Awad, Ana-Maria Copaescu, Joseph F. De Luca, Celia Zubrinich, Douglas Gin, Heather Cleland, Abby Douglas, Johannes S. Kern, Constance H. Katelaris, Francis Thien, Sara Barnes, James Yun, Winnie Tong, William B. Smith, Andrew Carr, Tara Anderson, Amy Legg, Jack Bourke, Laura K. Mackay, Ar Kar Aung, Elizabeth J. Phillips, Jason Trubiano
Summary: This study aims to examine the clinical presentation, drug causality, genomic predictors, potential diagnostic approaches, treatments, and long-term outcomes of severe cutaneous adverse reactions (SCAR) in Australia and New Zealand. The study will prospectively recruit adult and adolescent patients with SCAR and collect their DNA samples. Genomic testing and ex vivo testing will be performed to identify culprit drugs and prevent SCAR. Furthermore, the long-term outcomes of SCAR and patients' quality of life and mortality data will also be investigated.
Article
Pharmacology & Pharmacy
Ranita Kirubakaran, David W. Uster, Stefanie Hennig, Jane E. Carland, Richard O. Day, Sebastian G. Wicha, Sophie L. Stocker
Summary: A population pharmacokinetic model that considers the tacrolimus-azole antifungal interaction was developed for guiding tacrolimus dosing in heart transplant recipients.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Ling Li, Jannah Baker, Kasun Rathnayake, Sradha Kotwal, Johanna Westbrook, Richard Day, Zoltan Endre
Summary: This study examined the association between medication administration and the development of acute kidney injury (AKI). The results showed that medications known to reduce glomerular filtration rate (GFR) were associated with an increased risk of hospital-acquired AKI. Patients with potentially medication-related AKI had worse outcomes, including higher mortality rates and longer hospital stays.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Pharmacology & Pharmacy
Jane C. J. Spragg, Toni J. F. Michael, Parisa Aslani, Matthew J. Coleshill, Jian S. Chan, Richard O. Day, Sophie L. Stocker
Summary: This study aimed to explore the facilitators and barriers to allopurinol adherence among people with gout, as well as their perspectives on strategies to improve adherence, such as self-monitoring of urate concentration. The results showed that patient perceptions of the effectiveness and necessity of allopurinol influenced intentional adherence during medication initiation, implementation, and discontinuation. Providing accurate medical advice and informing patients of their urate control have the potential to improve adherence to allopurinol.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Pharmacology & Pharmacy
Jane E. Carland, Alexandra E. Stacy, Andrea L. Schaffer, Richard O. Day, Jonathan Brett, Stephanie E. Reuter, Sophie L. Stocker
Summary: Dose-prediction software is recommended for vancomycin dosing, but uncertainties exist in its implementation. A consultative therapeutic drug monitoring Advisory Service using dose-prediction software was able to achieve therapeutic targets in vancomycin therapy. Most dose adjustments recommended by the Service were accepted by treating teams. Publication of dose reports facilitated the attainment of therapeutic targets and could potentially improve outcomes and reduce staff workload.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Medicine, Research & Experimental
Hailemichael Z. Hishe, Sophie L. Stocker, Lisa K. Stamp, Nicola Dalbeth, Tony R. Merriman, Amanda Phipps-Green, Daniel F. B. Wright
Summary: The genetic determinants of the allopurinol dose-concentration relationship were studied, finding that genetic variability in urate transporters does not appear to influence oxypurinol pharmacokinetics. The final model predicted oxypurinol pharmacokinetics based on creatinine clearance, diuretic use, ethnicity, and body weight.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2023)
Article
Medical Laboratory Technology
Vincent Seah, Thulashigan Sreeharan, Danijela Kocic, Stephanie E. Reuter, Laila Girgis, Deborah J. E. Marriott, Sophie L. Stocker
Summary: The authors present a case of a 34-year-old male patient with amyopathic dermatomyositis who underwent therapeutic plasma exchange (TPE). Immunosuppression led to Aspergillus lentulus pulmonary infection, which was treated with super bioavailable-itraconazole. Therapeutic itraconazole concentrations were achieved after 2 weeks of treatment with dose adjustments. They observed a significant reduction in plasma itraconazole concentration during TPE, attributed to inadequate delay between itraconazole dosing and TPE initiation. Furthermore, post-TPE plasma concentration increased, indicating the redistribution of itraconazole from peripheral compartments back into plasma.
THERAPEUTIC DRUG MONITORING
(2023)
Article
Pharmacology & Pharmacy
Gina Chowdhury, Jane E. Carland, Shaun Kumar, Nick Olsen, Garry Graham, Gayathri Kumarasinghe, Christopher S. Hayward, Jerry R. Greenfield, Peter Macdonald, Richard O. Day, Sophie L. Stocker
Summary: This study investigated the safe use of metformin in heart failure patients with and without type 2 diabetes mellitus. The results showed that metformin use was safe and not significantly associated with plasma lactate concentrations. However, New York Heart Association class and sex were associated with higher plasma lactate concentrations.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
(2023)
Article
Immunology
Chuang-Wei Wang, Ming-Ying Wu, Chun-Bing Chen, Wei-Chen Lin, Jennifer Wu, Chun-Wei Lu, Wei-Ti Chen, Fang-Ying Wang, Rosaline Chung-Yee Hui, Min-Hui Chi, Tsu-Man Chiu, Ya-Ching Chang, Jing Yi Lin, Yang Yu-Wei Lin, Wan-Ting Tsai, Shuen-Iu Hung, Wen-Hung Chung
Summary: This study found that immune-mediated alopecia can occur following COVID-19 vaccinations, and it is associated with T cell-mediated cytotoxicity.
CLINICAL IMMUNOLOGY
(2023)
Article
Medicine, General & Internal
Tamara Y. Milder, Sophie L. Stocker, Melissa T. Baysari, Richard O. Day, Jerry R. Greenfield
Summary: This study explores the perspectives of cardiologists and nephrologists regarding initiating SGLT2i and their safety monitoring practices. It was found that non-heart-failure subspecialist cardiologists are reluctant to initiate SGLT2i due to various reasons, while nephrologists are confident in initiating these drugs. Government subsidisation plays a significant role in prescribing SGLT2i to non-diabetic patients. Therefore, interdisciplinary collaboration and clear guidance are needed to improve the confidence of specialists and ensure appropriate use of SGLT2i in patients with renal dysfunction.
INTERNAL MEDICINE JOURNAL
(2023)
Review
Infectious Diseases
Ricky Hao Chen, Toni Michael, Johanna Kuhlin, Thomas Schon, Sophie Stocker, Jan-Willem C. Alffenaar
Summary: This systematic review aims to evaluate the concentration-effect relationship of Pyrazinamide (PZA) in tuberculosis treatment. The study found that there is a positive correlation between PZA dose and antibacterial effect. Further dose optimization studies are justified.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
(2023)
Article
Infectious Diseases
K. P. Singh, A. C. C. Carvalho, R. Centis, L. D'Ambrosio, G. B. Migliori, S. G. Mpagama, B. C. Nguyen, R. E. Aarnoutse, A. Aleksa, R. van Altena, P. K. Bhavani, M. S. Bolhuis, S. Borisov, N. van't Boveneind-Vrubleuskaya, J. Bruchfeld, J. A. Caminero, I. Carvalho, J. G. Cho, L. Davies Forsman, M. Dedicoat, K. Dheda, K. Dooley, J. Furin, J. M. Garcia-Garcia, A. Garcia-Prats, A. C. Hesseling, S. K. Heysell, Y. Hu, H. Y. Kim, S. Manga, B. J. Marais, I. Margineanu, A-G. Martson, M. Munoz Torrico, H. M. Nataprawira, E. Nunes, C. W. M. Ong, R. Otto-Knapp, D. J. Palmero, C. A. Peloquin, A. Rendon, D. Rossato Silva, R. Ruslami, A. M. I. Saktiawati, P. Santoso, H. S. Schaaf, B. Seaworth, U. S. H. Simonsson, R. Singla, A. Skrahina, I. Solovic, S. Srivastava, S. L. Stocker, M. G. G. Stukenboom, E. M. Svensson, M. Tadolini, T. A. Thomas, S. Tiberi, J. Trubiano, Z. F. Udwadia, A. R. Verhage, D. H. Vu, O. W. Akkerman, J. W. C. Alffenaar, J. T. Denholm
Summary: This article presents clinical standards for the diagnosis and management of adverse effects (AE) to tuberculosis (TB) treatment. Eight clinical standards were identified, including counseling and evaluation for AE risk, assessment and management of AE, and training for healthcare workers. These standards aim to provide a consensus-based approach to minimize the impact of AE in TB treatment.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE
(2023)
Review
Infectious Diseases
Ruvimbo Dephine Mishi, Michael Andrew Stokes, Craig Anthony Campbell, Kevin William Plaxco, Sophie Lena Stocker
Summary: Therapeutic drug monitoring (TDM) is important for optimizing drug exposure in critically ill patients. This paper explores the potential of biosensors as a solution to current challenges in measuring plasma drug concentrations and discusses their application in TDM of antibiotics. The authors argue that biosensors hold great promise for enhancing drug exposure optimization in critically ill patients.
Meeting Abstract
Pharmacology & Pharmacy
K. A. Sinnappah, D. A. Hughes, B. Vrijens, J. K. Aronson, J. Holland, S. L. Stocker, D. F. B. Wright
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY
(2023)
Article
Oncology
Wen-Kuan Huang, Hung-Chih Hsu, Tsai-Sheng Yang, Chun-Wei Lu, Yi-Ru Pan, Chiao-En Wu, Wen-Hung Chung, Shuen-Iu Hung, Chun-Nan Yeh
Summary: This study investigated the impact of zinc supplementation on the severity of regorafenib-induced HFSR. The results have important clinical implications for the management and prevention of HFSR.
EUROPEAN JOURNAL OF CANCER
(2023)
